Clinical trial updates

Alpha-thalassaemia major

Alpha-thalassaemia major

  Update: 08 January 2021 No update available.   Update: 05 November 2020 Researchers at the University of California – San Francisco (UCSF) are conducting a Phase I clinical trial…
IMR-687

IMR-687

Update: 08 January 2021 No update available.   Update: 05 November 2020 The first thalassaemia patient has been dosed in the FORTE clinical trial – a Phase 2b clinical trial…
Rapamycin

Rapamycin

  Update: 08 January 2021 No update available.   Update: 05 November 2020 No update available.   Update: 25 August 2020 No update available.   Update: 31 May 2020 No…
Mitapivat (AG-348)

Mitapivat (AG-348)

  Update: 08 January 2021  Interim data was presented at ASH2020: 12/13 evaluable patients have achieved a Hb increase of more than ≥ 1.0 g/dL after a median of 3.1…
Apotransferrin

Apotransferrin

  Update: 08 January 2021 No update available.   Update: 05 November 2020 No update available.   Update: 25 August 2020 No update available.   Update: 31 May 2020 No…
Ferroportin inhibitors

Ferroportin inhibitors

VIT-2763   Update: 08 January 2021 No update available.   Update: 05 November 2020 No update available.   Update: 25 August 2020 Data presented at the EHA Congress in June…
SLN-124

SLN-124

Update: 08 January 2021 No update available.   Update: 05 November 2020 Initiated dosing in randomised, double-blind, placebo-controlled Phase 1 single ascending dose study of SLN124 in up to 24…
Denosumab

Denosumab

  Update: 08 January 2021 No update available.   Update: 05 November 2020 No update available.   Update: 25 August 2020 No update available.   Update: 31 May 2020 No…
Reblozyl

Reblozyl

  ‘BELIEVE’ Study in Adults with TDT β-thalassaemia   Update: 08 January 2021 Long term safety and efficacy results on REBLOZYL were presented at ASH2020 and demonstrated that a higher…
Schaltfläche "Zurück zum Anfang"